Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?

(2017) G. K. Abou-Alfa et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients

(2017) T. Yau et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

(2017) A. Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

(2017) R. S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels

(2012) Se Hun Kang et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model

(2011) Yanping Luo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2011) J.-W. Park et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

(2011) T. Yau et al.   CLINICAL CANCER RESEARCH

Current clinical use of biomarkers for epithelial ovarian cancer

(2010) Richard G Moore et al.   CURRENT OPINION IN ONCOLOGY

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma

(2010) Ghassan K. Abou-Alfa et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma

(2010) Jae Min Chun et al.   JOURNAL OF SURGICAL ONCOLOGY

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

(2010) D. Koeberle et al.   ONCOLOGIST

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies

(2009) Chiung-Ing Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

(2009) Sandrine Faivre et al.   LANCET ONCOLOGY

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

(2008) Stephen L. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma

(2008) Francisco A Durazo et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

(2008) Viraj J. Jasinghe et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

(2007) Andrew X. Zhu   CANCER